Results 11 to 20 of about 110,630 (313)

BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review [PDF]

Journal of Clinical Medicine, 2023
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths globally. BRAF mutation is present in about 10% of CRC patients and is associated with a poor response to chemotherapy. These patients have a relatively poor prognosis. This review aims to assess the efficacy and safety of BRAF inhibitors in BRAF-mutated CRC patients.
Wajeeha Aiman, Muhammad Ashar Ali, Samer Jumean, Ummul Asfeen, Jose Garcia, Murad Quirem, Amaar Ahmad, Mohammad Nabil Rayad, Osama Alkhlaifat, Bader Al Omour, Venkata S. Chemarthi, Michael Maroules, Gunwant Guron, Hamid Shaaban   +13 more
openaire   +3 more sources

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma [PDF]

Case Reports in Oncology, 2019
Approximately 50% of patients with metastatic melanoma harbor an activating BRAF mutation. Tumors with activating mutation <i>BRAF</i> gene proliferate excessively and can be treated with targeted BRAF-inhibitors in combination with MEK inhibitors. The most common BRAF mutation occurs at amino acid position 600. Other <i>BRAF</i>
Sara Bjursten, Christoffer Vannas, Stefan Filges, Florian Puls, Ankur Pandita, Henrik Fagman, Anders Ståhlberg, Max Levin   +7 more
openaire   +5 more sources

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma [PDF]

Oncotarget, 2014
Almost 50% of metastatic melanoma patients harbor a BRAF(V600) mutation and the introduction of BRAF inhibitors has improved their treatment options. BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. However, most patients develop
SPAGNOLO, FRANCESCO, GHIORZO, PAOLA, Queirolo, P.   +2 more
openaire   +4 more sources

Mechanisms of Reactivation and Its Interaction with [PDF]

Endocrinology and Metabolism, 2020
The telomerase reverse transcriptase (TERT) gene, which is repressed in most differentiated human cells, can be reactivated by somatic TERT alterations and epigenetic modulations.
Young Shin Song, Young Joo Park
doaj   +1 more source

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer

Archives of Medical Science, 2021
Introduction Detection of abnormalities in the KRAS, NRAS and BRAF genes is extremely important for proper qualification of colorectal cancer (CRC) patients for therapy with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies.
Aleksandra Bożyk, Paweł Krawczyk, Katarzyna Reszka, Kinga Krukowska, Agnieszka Kolak, Sławomir Mańdziuk, Kamila Wojas-Krawczyk, Rodryg Ramlau, Janusz Milanowski   +8 more
doaj   +1 more source

Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT

Efficacy and Mechanism Evaluation, 2022
Background: Complex trials with innovative designs are becoming increasingly common and offer the potential to improve patient outcomes in a shorter time frame.
Louise C Brown, David Fisher, Richard Adams, Jenny Seligmann, Matthew Seymour, Richard Kaplan, Susan D Richman, Philip Quirke, Rachel Butler, Helen Roberts, Janet Graham, Richard H Wilson, Timothy S Maughan   +12 more
doaj   +1 more source

Clinicopathological relevance of BRAF and SMO mutations in Chinese patients with ameloblastoma

All Life, 2023
Ameloblastomas are benign tumors associated with recurrence and morbidity. Mutations in the V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and smoothened (SMO) genes have been identified in ameloblastomas.
Chen Ruixue, Li Hexiang, Hou Yali, Li Xiangjun, Sun Xu, Wang Jie, Zhang Xudong   +6 more
doaj   +1 more source

BRAF in the cross-hairs [PDF]

Expert Review of Hematology, 2019
Hairy cell leukemia (HCL) is a rare, chronic B-cell lymphoproliferative disorder characterized by distinctive morphologic features and an indolent clinical course. The discovery of a recurrent activating mutation in BRAF (BRAF V600E) as a disease-defining genetic event in HCL has substantial diagnostic and therapeutic implications.
Mark B. Geyer, Omar Abdel-Wahab, Martin S. Tallman   +2 more
openaire   +2 more sources

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]

, 2014
BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Ferguson, J., Claudia Wellbrock, Erice, O., Margison, G.P., Goicoechea, I., Geoffrey P Margison, Margison, Geoffrey P, Wellbrock, C., Wellbrock, Claudia, Jennnifer Ferguson, Arozarena, Imanol, Goicoechea, Ibai, Imanol Arozarena, Ferguson, Jennnifer, Erice, Oihane, Oihane Erice, Ibai Goicoechea   +16 more
core   +1 more source

The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis [PDF]

, 2022
Objectives: Immune-checkpoint inhibitors (ICI) and targeted-therapies (TT) have become standard options for BRAF-V600 metastatic melanomas (MM). Recently, randomized trials (RCT) addressed the efficacy of combined approaches, with conflicting results. We
Marina Sahade, Mauricio Fernando Silva Almeida Ribeiro, Olavo Feher, Artur Katz, Allan Andresson Lima Pereira, Mariana Scaranti, Luiza Dib Batista Bugiato Faria, Rodrigo Ramella Munhoz, Camila Bragança Xavier, Tatiana Strava Correa, David Queiroz Borges Muniz, Gustavo dos Santos Fernandes   +11 more
core   +1 more source